|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1340739504 |
| 003 |
OCoLC |
| 005 |
20231120010658.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
220813s2022 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d SFB
|d OCLCF
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780323992268
|q (electronic bk.)
|
| 020 |
|
|
|a 0323992269
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323992251
|
| 020 |
|
|
|z 0323992250
|
| 035 |
|
|
|a (OCoLC)1340739504
|
| 050 |
|
4 |
|a QP572.P3
|
| 082 |
0 |
4 |
|a 612.44
|2 23
|
| 245 |
0 |
0 |
|a Parathyroid hormone /
|c Edited by Gerald Litwack.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 490 |
1 |
|
|a Vitamins and hormones ;
|v v. 120
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Parathyroid Hormone -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Structural pharmacology of PTH and PTHrP -- 1. Evolutionary biology of PTH and PTHrP -- 2. PTH mutations -- 3. PTHrP mutations -- 4. PTH and PTHrP pharmacology -- 4.1. PTH and PTHrP action is not identical -- 4.2. PTH and PTHrP signaling -- 4.3. PTH and PTHrP peptides providing insight into physiology -- Acknowledgments -- References -- Chapter Two: Salt inducible kinases and PTH1R action -- 1. Parathyroid hormone and PTH1R biology -- 2. PTH as anabolic therapies for osteoporosis -- 3. PTH action in osteocytes -- 4. Salt inducible kinases -- 5. Role of salt inducible kinases in responses to PTH in bone -- 6. Role of salt inducible kinases in responses to PTH in cartilage -- 7. Do salt inducible kinases participate in the renal actions of PTH? -- 8. PTH stimulates Cyp27b1 expression -- 9. PTH decreases phosphate reabsorption in proximal tubule -- 10. PTH increases calcium reabsorption in distal tubule -- 11. Summary and future directions -- References -- Chapter Three: Physiological regulation of phosphate homeostasis -- 1. Introduction -- 2. An overview of phosphate homeostasis -- 3. Intestinal phosphate absorption -- 4. Transcellular intestinal phosphate absorption and the role of NaPi-IIb -- 4.1. Other sodium-dependent transporters involved in transcellular phosphate absorption -- 4.2. Endocrine control of transcellular phosphate absorption -- 4.3. Paracellular intestinal phosphate absorption -- 4.4. Characterization and regulation of the paracellular pathway -- 5. Renal phosphate reabsorption -- 5.1. Regulation of renal phosphate reabsorption -- 6. Phosphate imbalance -- 6.1. Targeting renal phosphate transport -- 6.2. Targeting intestinal phosphate transport -- Conflict of interest -- References.
|
| 505 |
8 |
|
|a Chapter Four: The parathyroid glands and parathyroid hormone: Insights from PTH gene mutations -- 1. History of the parathyroid gland and parathyroid hormone -- 2. Sequence and structure of the PTH gene -- 3. Synthesis, processing, and secretion of PTH -- 4. Chromosomal rearrangement of the PTH gene -- 4.1. PTH promotor/cyclin D1 rearrangement -- 4.2. DNA rearrangement in the upstream regulatory region of the PTH gene -- 5. Intragenic polymorphisms of the PTH gene -- 6. Mutations in the PTH signal peptide -- 6.1. Heterozygous PTH C18R mutation -- 6.2. Homozygous PTH S23P mutation -- 6.3. Homozygous PTH S23X mutation -- 6.4. Heterozygous p.Met1_Asp6del PTH mutation -- 6.5. Heterozygous M14K PTH mutation -- 7. PTH exon skipping mutation -- 7.1. Homozygous PTH exon 2 skipping mutation -- 8. Mutations in the mature PTH peptide -- 8.1. Heterozygous PTH R83X mutation (R52X in mature PTH) -- 8.2. Homozygous PTH R56C mutation (R25C in mature PTH) -- 8.3. Homozygous PTH S32P mutation (S1P in mature PTH) -- 9. Conclusions and future directions -- Acknowledgments -- Conflicts of interest -- References -- Chapter Five: Modulation of PTH1R signaling by an extracellular binding antibody -- 1. Introduction -- 1.1. Parathyroid hormone, parathyroid 1 receptor and bone development -- 1.2. The PTH1R -- 1.3. PTH1R and biased agonism -- 1.4. Monoclonal antibodies -- 2. Results -- 2.1. Antibody discovery overview -- 2.2. ECD-ScFvhFc and PTH1R signaling -- 2.3. Characterization of antibody binding to full length receptor -- 2.4. Mapping the ECD-scFvhFc binding site -- 3. Discussion -- Acknowledgments -- References -- Chapter Six: Parathyroid hormone-related protein (PTHrP) and malignancy -- 1. Background -- 1.1. Calcium metabolism and regulation -- 1.1.1. Bone metabolism -- 1.1.2. Renal regulation -- 1.2. Discovery of PTHrP -- 1.3. Cloning of PTHrP.
|
| 505 |
8 |
|
|a 1.4. Structure of PTHrP -- 1.4.1. Gene structure -- 1.4.2. Functional domains of PTHrP -- 1.4.2.1. Interactions with cell surface receptors (via amino-terminal domain) -- 1.4.2.2. Other functional domains of PTHrP -- 1.4.2.3. Mid-molecule portion (residues 35-84) -- 1.4.2.4. Nuclear localization sequence (residues 87-107) -- 1.4.2.5. COOH-terminal fragments (residues 107 and beyond) -- 1.4.2.6. Detection of PTHrP -- 2. Characterization of MAH -- 2.1. Differences between PTHrP and PTH manifestations -- 2.2. Pathophysiologies of MAH (PTHrP associated and unassociated) -- 2.2.1. Humoral hypercalcemia of malignancy (HHM) -- 2.2.2. Osteolytic metastases with local release of cytokines -- 2.2.3. Tumor production of 1,25D -- 2.2.4. Tumor production and ectopic secretion of PTH -- 3. Role of PTHrP in tumor progression -- 3.1. Expression and regulation of PTHrP in tumors -- 3.2. Relationship of PTHrP with the bone microenvironment -- 3.3. Extra-skeletal actions of PTHrP in malignancy -- 4. Clinical implications of MAH -- 4.1. Clinical manifestations of hypercalcemia -- 4.2. Diagnostic approach and investigation of hypercalcemia -- 4.3. Therapeutic modalities for MAH and skeletal metastases -- 4.3.1. Clinically approved therapies and their limitations -- 4.3.2. Investigational approaches to controlling PTHrP production and action -- 4.3.3. Potential non-skeletal roles for anti-PTHrP therapies -- 5. Conclusion -- Acknowledgments -- Disclaimer -- References -- Further reading -- Chapter Seven: Parathyroid hormone-related protein (PTHrP)-dependent modulation of gene expression signatures in cancer cells -- 1. Parathyroid hormone-related protein (PTHrP): A brief insight into its structure and function -- 2. Bone cancer cells -- 2.1. Osteosarcoma cells -- 2.2. Giant bone tumor cells -- 3. Breast cancer cells -- 3.1. 8701-BC cell line -- 3.2. MDA-MB231 cell line.
|
| 505 |
8 |
|
|a 6.2. Bilateral internal jugular venous sampling -- 6.3. USG guided parathyroid biopsy with PTH washout -- 7. Elevated parathyroid hormone levels postsurgery -- 8. Future directions -- References -- Chapter Eleven: Gene expression profiles in parathyroid adenoma and normal parathyroid tissue -- 1. Introduction -- 1.1. Synthesis of PTH -- 1.2. Regulation of PTH secretion -- 2. Summary of germline and somatic genetics in sporadic parathyroid adenoma -- 3. Comparative genomic expression -- 3.1. Genes involved in cell cycle regulation -- 3.2. Genes involved in growth factors -- 3.3. Genes involved in apoptotic pathway -- 3.4. Genes involved in PTH synthesis or regulation pathway -- 3.4.1. GCM2 -- 3.4.2. CaSR -- 3.4.3. Klotho -- 3.5. Next-generation sequencing analysis -- 3.6. Differential microRNA expression -- Acknowledgment -- References -- Chapter Twelve: Renal hyperparathyroidism -- 1. Pathophysiology of renal hyperparathyroidism -- 1.1. Histology of parathyroid gland (Fig. 1) -- 1.2. Klotho-FGF-23-endocrine axes and calcium-phosphate homeostasis in renal hyperparathyroidism (Fig. 2) (Brown et al., ... -- 2. Causes of renal hyperparathyroidism -- 2.1. Hypocalcemia -- 2.2. Decreased circulating calcitriol levels -- 2.3. Hyperphosphatemia -- 2.4. Parathyroid cell proliferation and tumorigenesis -- 3. Medical treatment of renal hyperparathyroidism (Table 1) -- 3.1. Management goals -- 3.2. Diet therapy and phosphorus restriction -- 3.3. Phosphorus adsorbents -- 3.4. Vitamin D receptor activators -- 3.5. Drugs for osteoporosis -- 3.6. Calcimimetics -- 3.7. Parathyroidectomy -- 3.7.1. Surgical procedure -- 3.7.2. An algorithm to identify parathyroid glands -- 3.7.3. Intraoperative intact PTH monitoring -- 3.7.3.1. The necessity of intraoperative PTH monitoring -- 3.7.4. Measurement of intact PTH.
|
| 650 |
|
0 |
|a Parathyroid hormone.
|
| 650 |
|
2 |
|a Parathyroid Hormone
|0 (DNLM)D010281
|
| 650 |
|
6 |
|a Parathormone.
|0 (CaQQLa)201-0090840
|
| 650 |
|
7 |
|a Parathyroid hormone
|2 fast
|0 (OCoLC)fst01053221
|
| 700 |
1 |
|
|a Litwack, Gerald.
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780323992268
|
| 776 |
0 |
8 |
|c Original
|z 0323992250
|z 9780323992251
|w (OCoLC)1292588270
|
| 776 |
0 |
8 |
|i Print version:
|t PARATHYROID HORMONE.
|d [S.l.] : ELSEVIER ACADEMIC PRESS, 2022
|z 0323992250
|w (OCoLC)1292588270
|
| 830 |
|
0 |
|a Vitamins and hormones ;
|v v. 120.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00836729/120
|z Texto completo
|
